News Digest / Lukas Schmidt

Author: Lukas Schmidt

07:53am, Monday, Jul 13, 2026
HSBC downgraded AstraZeneca from Buy to Hold and lowered its price target after a Phase 3 trial missed key goals, citing delayed catalysts and potential risks to the drugmaker's R&D reputation, leading to share price dips in London and U.S. markets.